IMUX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Immunic Inc (IMUX) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company has secured substantial funding, is advancing its multiple sclerosis treatment program, and has upcoming catalysts like Phase 3 trial data by the end of 2026. Despite its current financial losses, its strategic positioning and potential for growth in the biotech sector make it a promising long-term investment.
The MACD is positive and contracting, indicating a potential upward momentum. RSI is neutral at 66.022, and moving averages are converging, suggesting no strong trend. The stock is trading near its pivot level of 0.946, with resistance at 1.127 and support at 0.764.
Successful $400 million private placement, with $200 million upfront proceeds.
Advancing Phase 3 trials for multiple sclerosis treatment, with top-line data expected by the end of
Plans to submit a New Drug Application for vidofludimus calcium in mid-
Appointment of new leadership to strengthen commercial expertise.
Negative net income of -$25.58 million in Q3
Declining EPS, down 45.83% YoY.
High volatility in stock price, with implied volatility at 263.16%.
In Q3 2025, the company reported no revenue growth (0% YoY) and a net income loss of -$25.58 million, although this represented a 4.97% improvement YoY. EPS dropped significantly by 45.83% YoY to -0.13.
No recent analyst rating or price target data available.
